Laron syndrome'2 is a unique model of a peptide hormone receptor defect that has enabled the study of the physiology of insulin-like growth factor-I (IGF-I) deprivation and recently, with the initiation of its use in clinical treatment, the physiology of IGF-I activity. ' The recent advances in the study and treatment of this disease will be reviewed. Definition 16 Irrespective of the defect, location or size, the growth hormone receptor becomes inactive leading to a full phenotypic expression of the disease.
Pathophysiology
The inability to bind to its receptor makes the pituitary growth hormone an ineffective hormone, resulting in low circulating serum IGF-I,9 which in turn by a negative feedback mechanism leads to an abnormally increased growth hormone releasing hormone and growth hormone synthesis.8 Serum GHBP is also low in most instances. The growth hormone dependent insulin-like growth factor binding protein (IGFBP)-3 is also reduced" whereas the nongrowth hormone dependent IGFBP-1 and 2 are abundant.'" The number of IGF-I receptors in target tissue is also increased (Eshet et al, in press, J Mol Endocrinol). The main typical biochemical changes are hypoglycaemia, mainly in childhood, and a tendency for increased blood lipids.
Treatment
The biosynthesis of IGF-I by recombinant DNA technology a few years ago enabled the initiation of clinical trials. The induction of hypoglycaemia, suppression of insulin, growth hormone, growth hormone releasing hormone, and thyroid stimulating hormone by an intravenous injection of 75 tg/kg IGF-I (FK-780 Fujisawa Pharmaceutical Co Ltd) in 10 patients with Laron syndrome revealed the responsiveness of these patients to the exogenous hormone they cannot generate, and raised the hope that long term treatment will also affect linear growth. '9 20 Despite the fact that the biological half life of exogenous IGF-I in patients with Laron syndrome was found to be half of that found in healthy subjects,2' explained by low values of IGFBP-3,'' daily injections of IGF-I for one week induced a rise in procollagen IJI. 
